AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01927367 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Decision Support System for AF
Description: A web-based clinical decision support system, computerizing the Canadian AF clinical guidelines and best-practice approaches, to support primary care providers and patients in optimizing and standardizing AF care.
Study NCT04372030 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Online questionnaire
Description: this is an online questionnaire collecting retrospective data on health care use and non-use
Study NCT02375113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: soy supplementation
Description: Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months.~Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone.
Study NCT02375113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy supplementation
Description: Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months.~Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone.
Study NCT03418415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: multi-electrode catheter-based renal denervation
Study NCT04606082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony Stimulated Factor
Description: GCSF was intrauterine injected once at ovum pick up day
Study NCT04606082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropins
Description: 500 IU of HCG was injected intrauterine once at ovum pick up day
Study NCT01648205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo will be given for first month.
Study NCT01648205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Patients will receive ranolazine 1000mg bid for subsequent 5 months.
Study NCT00477971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: No administration information given
Study NCT00477971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given orally
Study NCT00477971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan
Description: Given IV or orally
Study NCT00477971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV or orally
Study NCT00477971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Given on day 0
Study NCT02882009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab as a HCLF will be administered via SC injection according to assigned treatment sequence.
Study NCT02882009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.
Study NCT03725280 — intervention group
Intervention type: PROCEDURE
Intervention: IVF
Description: None interventional study (Collection of ovarian follicular fluid during IVF treatment)
Study NCT00241280 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Study NCT00241280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: galyfilcon A
Study NCT00830596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HVLA-SM
Description: High velocity, low amplitude lumbo-pelvic manipulation
Study NCT00830596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LVVA-SM
Description: Low velocity, variable amplitude lumbo-pelvic manipulation
Study NCT00830596 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Intervention
Description: 2 weeks of light effleurage and a sham mechanically-assisted chiropractic treatment followed by 4 weeks active care with full spine spinal manipulation
Study NCT02876354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menaquinone
Description: Patients on hemodialysis will be supplemented by 360 μg /d of menaquinone for 4 weeks. At baseline they will have a lateral abdominal X-Ray and dosage of dp-ucMGP. At the end of the study patients will have a second measurement of dp-ucMGP levels.
Study NCT04689633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve block
Description: bilateral ultrasound-guided posterior quadratus lumborum block was done in the lateral decubitus and linear or curvilinear probe was used according to the depth and placed in the midaxillary line in the transverse plane above the iliac crest
Study NCT01678677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838500A (formulation 1)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT01678677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838501A (formulation 2)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT01678677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838502A (formulation 3)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT01678677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838503A (formulation 4)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT01678677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838504A (formulation 5)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT01678677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838505A (formulation 6)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT01678677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838508A (formulation 7)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT01678677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHI vaccine GSK2838509A (formulation 8)
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT01678677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT03218072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX01
Description: a potential rituximab biosimilar
Study NCT03604991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample
Study NCT03604991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03604991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT03604991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03604991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02513485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa+carbidopa
Description: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.
Study NCT02513485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Study NCT04363255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Injection
Description: Etoposide(100mg/m2, d1-3, q3w) combined with platinum was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
Study NCT04363255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Injection
Description: Carboplatin(AUC 5, d1, q3w) or Cisplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
Study NCT04363255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Cisplatin(75mg/m2, d1, q3w) or carboplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
Study NCT04363255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: After 4-6 cycles of chemotherapy, JS001(240mg, d1, q3w) combined with anlotinib were followed and continued until disease progression.
Study NCT04363255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: After 4-6 cycles of chemotherapy, anlotinib(12mg qd, d1-14, q3w) combined with JS001 were followed and continued until disease progression.
Study NCT05171595 — intervention group
Intervention type: DEVICE
Intervention: Lifetouch single-lead ECG monitoring
Description: The continuous wireless monitoring is a single-lead ECG patch (Isansys Life Touch patch) which consists of two ECG electrodes placed on the left side of the patients' thorax. The patch measures respiratory rate (RR), heart rate (HR), heart rate variability (HRV) and electrocardiogram (ECG)s.
Study NCT05171595 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: high-sensitive TnT measurements
Description: Another monitoring device in the study was the plasma concentration of high-sensitive cardiac troponin T (hsTnT).
Study NCT04359550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
Description: Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
Study NCT04359550 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01008007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid
Description: One Viusid bag (4 grams, orally administered) every 8 hours, for 6 days in combination with the conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
Study NCT03604991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01008007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
Study NCT00867009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Induction therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles Maintenance therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation
Study NCT00867009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Induction therapy: 75 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles
Study NCT00867009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Induction therapy: Loading dose of 400 mg/m², intravenous, on Day 1 of cycle 1, then 250 mg/m², intravenous, weekly for 4 to 6 cycles, 21 day cycles~Maintenance therapy: 250 mg/m², intravenous, weekly until progressive disease or treatment discontinuation
Study NCT00705653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-11047
Description: PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).
Study NCT03383172 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I Can Problem Solve (ICPS) Program
Description: The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
Study NCT03383172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Can Problem Solve (ICPS) Program
Description: The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
Study NCT01803919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Alloy-Coated Urinary Catheters
Study NCT01803919 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional Urinary Catheter
Study NCT03992859 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous serratus plane block
Description: Peripheral nerve catheter placed by the surgeon at the end of surgery
Study NCT02059486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Choice
Description: The curriculum provides sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress.
Study NCT01133483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine HCl + Pseudoephedrine HCl
Description: Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited
Study NCT01133483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl + Pseudoephedrine HCl
Description: Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited
Study NCT02547454 — intervention group
Intervention type: DRUG
Intervention: Methoxy polyethylene glycol-epoetin beta
Study NCT00147199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil
Description: Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.
Study NCT00147199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation solution
Description: Doses are titrated to 9 breaths four times daily.
Study NCT00580606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerinated peanut allergenic extract
Description: Glycerinated peanut extract delivered sublingually.
Study NCT00580606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for peanut extract (glycerin)
Description: Placebo (glycerin) delivered sublingually.
Study NCT03066271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise +
Description: Usual care
Study NCT03066271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control +
Description: Usual care
Study NCT02980445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor activity 1
Description: 40-minute outdoor activity
Study NCT02980445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor activity 2
Description: Dose 1 plus an additional 40-minute outdoor activities during recesses
Study NCT03604991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT00240162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584
Study NCT03604991 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT00788476 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey packets to adult (>18 years old) childhood cancer survivors who return to MDACC for follow-up appointments within the next 12-months and conduct a mailed survey with the remaining participants and their primary caregivers i.e. guardians of survivors who are currently under age 18.
Study NCT02401815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX9486
Description: PLX9486 will be administered per dose and schedule specified in the arm.
Study NCT03888404 — intervention group
Intervention type: OTHER
Intervention: Pregnancy preferences (Aim 1)
Description: The primary exposure of interest for Aim 1 will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
Study NCT03888404 — intervention group
Intervention type: OTHER
Intervention: Sociocultural environment (Aim 2)
Description: For Aim 2 will assess the roles of contextual and individual variables on pregnancy decision-making and care-seeking outcomes (including state political environment, stigma, social emotional and instrumental support, feelings about the pregnancy, SES).
Study NCT02401815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: Pexidartinib capsules will be administered per dose and schedule specified in the arm.
Study NCT02401815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered per dose and schedule specified in the arm.
Study NCT04575922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered into vein by intravenous infusion every 2 weeks over 6 week study cycle.
Study NCT04575922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Administered into vein by intravenous infusion day 1 of each 6 week study cycle.
Study NCT04575922 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 3 radiation treatments, every other weekday or 2 days during week 1 of cycle 1 only of study.
Study NCT02846779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity
Description: Low intensity telepharmacy outreach
Study NCT02846779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity
Description: Moderate intensity telepharmacy outreach
Study NCT02846779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity
Description: High intensity telepharmacy outreach
Study NCT00260351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Verocell Rabies Vaccine
Description: 0.1 mL, ID (TRC regimen)
Study NCT00260351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Verocell Rabies Vaccine
Description: 0.5 mL, IM (ZAGREB regimen)
Study NCT00260351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Verocell Rabies Vaccine
Description: 0.5 mL, IM (ESSEN regimen)
Study NCT00531999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir then lopinavir/ritonavir
Description: raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
Study NCT00531999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir then raltegravir
Description: lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
Study NCT01880385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: During neoadjuvant phase: 15 mg/kg, d1 q3w, 4 cycles
Study NCT01880385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
Study NCT01880385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
Study NCT01880385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
Study NCT01880385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Adjuvant: 100 mg/m2 q3w, 4 cycles
Study NCT01880385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Adjuvant: 8 mg/kg d1 in the 1st cycle then 6 mg/kg for d1 q3w, 17 cycles if tumor overexpress HER2